西多福韦对自然感染人乳头瘤病毒16型的头颈部鳞状细胞癌（SCCHN）细胞系的抗病毒活性可提高放射敏感性。

Antiviral activity of Cidofovir on a naturally human papillomavirus-16 infected squamous cell carcinoma of the head and neck (SCCHN) cell line improves radiation sensitivity.

作者信息

Sirianni Nicky, Wang Jun, Ferris Robert L

机构信息

Department of Otolaryngology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.

出版信息

Oral Oncol. 2005 Apr;41(4):423-8. doi: 10.1016/j.oraloncology.2004.11.003.

DOI:10.1016/j.oraloncology.2004.11.003

PMID:15792615

Abstract

High risk HPV types 16 and 18 are associated with cervical cancer and squamous cell carcinoma of the head and neck (SCCHN). Cidofovir is an antiviral drug used to treat HPV-induced laryngeal papillomatosis and other viral infections, with initial reports suggesting activity in cervical carcinoma cells. We investigated the effects of Cidofovir on a naturally HPV-16-transformed SCCHN cell line (UPCI:SCC090), in comparison with a cervical carcinoma cell line (CasKi) of similar viral characteristics, to evaluate its therapeutic potential. HPV-16 gene transcription was only marginally reduced, and the antiviral and p53 restorative effects were modest in SCC90 cells. However, combination with irradiation enhanced the effects of Cidofovir treatment on these cells. Several days of treatment were required for this effect, which may limit its clinical applicability. Future therapies for HPV-associated tumors may include intralesional antiviral therapy in combination with radiation therapy, but optimization for clinical utility is needed.

摘要

高危型人乳头瘤病毒16型和18型与宫颈癌以及头颈部鳞状细胞癌（SCCHN）相关。西多福韦是一种抗病毒药物，用于治疗人乳头瘤病毒引起的喉乳头状瘤病和其他病毒感染，最初的报告表明其对宫颈癌细胞有活性。我们研究了西多福韦对一种自然感染人乳头瘤病毒16型转化的头颈部鳞状细胞癌细胞系（UPCI:SCC090）的影响，并与具有相似病毒特征的宫颈癌细胞系（CasKi）进行比较，以评估其治疗潜力。在SCC90细胞中，人乳头瘤病毒16型基因转录仅略有降低，抗病毒和恢复p53的作用较为适度。然而，与放疗联合可增强西多福韦对这些细胞的治疗效果。产生这种效果需要数天的治疗，这可能会限制其临床应用。未来针对人乳头瘤病毒相关肿瘤的治疗可能包括病灶内抗病毒治疗联合放射治疗，但需要对其临床效用进行优化。